Back to Feed
ClinicalTrials.gov|Clinical Trial
Nanobody-Based CD19/CD20 Tandem Dual CAR-T-cell Therapy of Relapsed/Refractory B-Cell Lymphoma
Affiliated Hospital to Academy of Military Medical Sciences
Abstract
This is a single arm study to evaluate the safety and efficacy of Nanobody-Based CD19/CD20 Tandem Dual CAR-T-cell therapy for Relapsed/Refractory B-Cell Lymphoma Phase: EARLY_PHASE1 Status: NOT_YET_RECRUITING Conditions: Relapsed/Refractory B-Cell Lymphoma Interventions: CD19/CD20 Tandem Dual CAR-T
Keywords
Relapsed/Refractory B-Cell Lymphoma